New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 1, 2014
05:35 EDTCLVSClovis CO-1686 safety concerns seem overdone, says Mizuho
After meeting with management, Mizuho believes concerns around safety for Clovis' CO-1686 appear overdone. The firm says Clovis management remains bullish on CO-1686, with PFS being the key differentiator. It reiterates a Buy rating on the stock.
News For CLVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2014
07:09 EDTCLVSClovis can remain ahead of competitor, says Stifel
Subscribe for More Information
06:02 EDTCLVSAstraZeneca data raises bar for Clovis, says Mizuho
Subscribe for More Information
September 28, 2014
12:42 EDTCLVSClovis announces preliminary Phase 2 results from the ARIEL2
Clovis Oncology announced preliminary Phase 2 results from the ARIEL2, Assessment of Rucaparib In Ovarian Cancer Trial, study and updated results from the ongoing Phase 1/2 monotherapy study of rucaparib. Rucaparib is the company’s investigational oral, potent, small molecule inhibitor of PARP1 and PARP2 being developed for the treatment of platinum-sensitive ovarian cancer in patients with homologous recombination deficient tumors, defined as those with BRCA mutations and other DNA repair deficiencies. These data are being presented today at the European Society of Medical Oncology 2014 Congress in Madrid. "New treatments are desperately needed for women with ovarian cancer. The data presented for rucaparib in ovarian cancer demonstrate compelling clinical activity and tolerability in patients with BRCA mutations,” said Professor Iain McNeish, Professor of Gynaecological Oncology, Institute of Cancer Sciences, University of Glasgow and one of the two principal investigators of the ARIEL2 study. “Even more encouraging are the preliminary data from ARIEL2, which show that tumor HRD analysis can identify a broader range of patients who may benefit from rucaparib therapy. HRD analysis may be a more robust and precise method to select patients for PARP inhibitor therapy than platinum sensitivity alone. I am delighted to be involved in this study, which may ultimately lead to an additional treatment option, not only for germline BRCA mutation carriers but also for large numbers of ovarian cancer patients, for whom few options exist today.” “We are enthusiastic about the possibility of identifying ovarian cancer patients beyond those with germline BRCA mutations who may benefit from rucaparib therapy with the ARIEL2 study,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “And we look forward to sharing the first clinical outcome data at the ENA Symposium in November, which were accepted for an oral plenary session. We believe we are the only company seeking to prospectively demonstrate a PARP inhibitor’s activity in a molecularly-selected ovarian cancer population beyond germline BRCA mutations, and this may have the potential to meaningfully differentiate rucaparib.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use